Affinity Asset Advisors, LLC
Long book
$1.68B
Q1 2026
Positions
92
Top-10 weight
43%
concentration
Last quarter
+24.0%
SPY +14.8%
Turnover
29%
of book per quarter
Strategy in plain words
auto-generated from filingsAffinity Asset Advisors, LLC is a diversified fundamental manager, specialised in healthcare (98% of the long book), running a $1.68B US long book across 92 positions.
The portfolio is moderately concentrated (top 10 ≈ 43% of the book). The portfolio is actively managed, with meaningful quarterly turnover. Current anchor positions: APOGEE THERAPEUTICS INC, XENON PHARMACEUTICALS INC, ERASCA INC, INSMED INC, ROIVANT SCIENCES LTD.
Over the last 9 quarters its long book ran on average 3.5pp per quarter ahead of the S&P 500, beating the index in 5 of 9 quarters. We rate its filings as signal-bearing: position changes reflect genuine views.
Implied long-book return vs S&P 500
methodology: positions priced quarterly, no shorts/options Fund long book S&P 500
Q1 2024
-10.3%
Q2 2024
+10.2%
Q3 2024
-7.9%
Q4 2024
-20.1%
Q1 2025
+3.1%
Q2 2025
+34.4%
Q3 2025
+30.8%
Q4 2025
+7.7%
Q1 2026
+24.0%
Sector allocation
Healthcare 93%
Other 5%
Materials 1%
Financials 1%
Long book by quarter
What does Affinity Asset own?
Q1 2026 13F| Company | Sector | Shares | Value | % of book | Change |
|---|---|---|---|---|---|
| APGE APOGEE THERAPEUTICS INC | Healthcare | 1.3M | $108.2M | 6.5% | +4.0% |
| XENE XENON PHARMACEUTICALS INC | Healthcare | 1.7M | $97.4M | 5.8% | +34.0% |
| ERAS ERASCA INC | Healthcare | 5.3M | $86.6M | 5.2% | +37.2% |
| INSM INSMED INC | Healthcare | 480.0K | $78.5M | 4.7% | +6.7% |
| ROIV ROIVANT SCIENCES LTD | Healthcare | 2.8M | $77.6M | 4.6% | +64.7% |
| SYRE SPYRE THERAPEUTICS INC | Healthcare | 1.3M | $64.5M | 3.8% | -10.7% |
| PRAX PRAXIS PRECISION MEDICINES I | Healthcare | 170.0K | $54.8M | 3.3% | -8.1% |
| ANAB ANAPTYSBIO INC | Healthcare | 940.0K | $52.1M | 3.1% | +111.4% |
| ALKS ALKERMES PLC | Healthcare | 1.4M | $47.7M | 2.8% | +35.0% |
| CYTK CYTOKINETICS INC | Healthcare | 700.5K | $46.2M | 2.8% | -12.4% |
| ACLXGBX ARCELLX INC | — | 362.8K | $41.7M | 2.5% | -30.7% |
| NUVL NUVALENT INC-A | Healthcare | 300.0K | $30.7M | 1.8% | -7.0% |
| 430 TERNS PHARMACEUTICALS INC | — | 562.6K | $29.7M | 1.8% | +2.3% |
| DNTH DIANTHUS THERAPEUTICS INC | Healthcare | 350.0K | $29.4M | 1.8% | +204.3% |
| LXEO LEXEO THERAPEUTICS INC | Healthcare | 5.1M | $29.0M | 1.7% | +57.8% |
| COGT COGENT BIOSCIENCES INC | Healthcare | 750.0K | $28.9M | 1.7% | +114.3% |
| MDGL MADRIGAL PHARMACEUTICALS INC | Healthcare | 55.0K | $28.8M | 1.7% | +76.7% |
| STRO SUTRO BIOPHARMA INC | Healthcare | 1.1M | $26.6M | 1.6% | +42.9% |
| FBRX FORTE BIOSCIENCES INC | Healthcare | 1.0M | $26.2M | 1.6% | +2.3% |
| ORKA ORUKA THERAPEUTICS INC | Healthcare | 499.7K | $24.5M | 1.5% | -37.7% |
| TRVI TREVI THERAPEUTICS INC | Healthcare | 2.0M | $23.9M | 1.4% | -7.0% |
| OVID OVID THERAPEUTICS INC | Healthcare | 10.6M | $23.6M | 1.4% | +48.8% |
| ELVN ENLIVEN THERAPEUTICS INC | Healthcare | 586.9K | $23.0M | 1.4% | New |
| MLYS MINERALYS THERAPEUTICS INC | Healthcare | 750.0K | $20.3M | 1.2% | +2.7% |
| AVTX AVALO THERAPEUTICS INC | Healthcare | 1.3M | $20.0M | 1.2% | +27.6% |
| PTGX PROTAGONIST THERAPEUTICS INC | Healthcare | 172.1K | $18.1M | 1.1% | Held |
| CLDX CELLDEX THERAPEUTICS INC | Materials | 500.0K | $15.9M | 0.9% | +42.9% |
| ZURA ZURA BIO LTD | Healthcare | 2.6M | $15.3M | 0.9% | +41.4% |
| NRIX NURIX THERAPEUTICS INC | Healthcare | 967.6K | $15.0M | 0.9% | Held |
| SVRA SAVARA INC | Healthcare | 2.5M | $13.7M | 0.8% | -10.2% |
| CATX PERSPECTIVE THERAPEUTICS INC | Healthcare | 3.2M | $13.2M | 0.8% | +954.9% |
| HLXC HELIX ACQUISITION CORP-CL A | Financials | 1.3M | $12.7M | 0.8% | New |
| ARWR ARROWHEAD PHARMACEUTICALS IN | Healthcare | 200.0K | $12.5M | 0.7% | +185.7% |
| DMRA DAMORA THERAPEUTICS INC | Healthcare | 450.0K | $11.7M | 0.7% | New |
| EPRX EUPRAXIA PHARMACEUTICALS INC | Healthcare | 1.6M | $11.5M | 0.7% | +429.7% |
| ANRO ALTO NEUROSCIENCE INC | Healthcare | 500.0K | $11.2M | 0.7% | New |
| BBIO BRIDGEBIO PHARMA INC | Healthcare | 150.0K | $11.1M | 0.7% | -53.1% |
| CGEM CULLINAN THERAPEUTICS INC | Healthcare | 781.3K | $11.1M | 0.7% | -59.6% |
| WVE WAVE LIFE SCIENCES LTD | Healthcare | 1.4M | $10.2M | 0.6% | -48.1% |
| VERA VERA THERAPEUTICS INC | Healthcare | 250.0K | $10.1M | 0.6% | Held |
| TYRA TYRA BIOSCIENCES INC | Healthcare | 257.5K | $9.9M | 0.6% | New |
| RVMD REVOLUTION MEDICINES INC | Healthcare | 100.0K | $9.7M | 0.6% | Held |
| JBIO JADE BIOSCIENCES INC | Healthcare | 640.0K | $9.0M | 0.5% | -10.5% |
| TVTX TRAVERE THERAPEUTICS INC | Healthcare | 300.0K | $8.9M | 0.5% | Held |
| NAMS NEWAMSTERDAM PHARMA CO NV | Healthcare | 275.0K | $8.8M | 0.5% | Held |
| KRRO KORRO BIO INC | Healthcare | 706.9K | $8.0M | 0.5% | New |
| CRSP CRISPR THERAPEUTICS AG | Healthcare | 150.0K | $7.1M | 0.4% | New |
| SGP SPYGLASS PHARMA INC | Healthcare | 250.0K | $6.5M | 0.4% | New |
| IBIO IBIO INC | Healthcare | 3.1M | $5.9M | 0.4% | +51.0% |
| ESTA ESTABLISHMENT LABS HOLDINGS | Healthcare | 100.0K | $5.7M | 0.3% | -50.0% |
13F filing history
| Period | Form | Filed | Entries | Reported value | Flags | Source |
|---|---|---|---|---|---|---|
| Q1 2026 | 13F-HR | May 14, 2026 | 105 | $1.94B | canonical | SEC ↗ |
| Q4 2025 | 13F-HR | Feb 13, 2026 | 95 | $1.76B | canonical | SEC ↗ |
| Q3 2025 | 13F-HR | Nov 13, 2025 | 96 | $1.15B | canonical | SEC ↗ |
| Q2 2025 | 13F-HR | Aug 13, 2025 | 91 | $732.2M | canonical | SEC ↗ |
| Q1 2025 | 13F-HR | May 14, 2025 | 98 | $1.05B | canonical | SEC ↗ |
| Q4 2024 | 13F-HR | Feb 13, 2025 | 85 | $746.0M | canonical | SEC ↗ |
| Q3 2024 | 13F-HR | Nov 13, 2024 | 86 | $732.8M | canonical | SEC ↗ |
| Q2 2024 | 13F-HR | Aug 14, 2024 | 98 | $867.5M | canonical | SEC ↗ |
| Q1 2024 | 13F-HR | May 14, 2024 | 95 | $807.8M | canonical | SEC ↗ |